<Summary id="CDR0000062745" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Male breast cancer treatments include surgery with or without radiation therapy, chemotherapy, endocrine therapy, and/or HER2-directed therapy. Get detailed information about clinical features, diagnosis, and treatment of early, locally advanced, and metastatic male breast cancer in this summary for clinicians. </SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq">Male Breast Cancer (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq">Male Breast Cancer (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000041338">male breast cancer</TermRef></MainTopics><SummaryAbstract><Para id="_272">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of male breast cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_273">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>male breast cancer</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Male Breast Cancer Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Male Breast Cancer Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Male Breast Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000041338">male breast cancer</SpecificDiagnosis></SectMetaData><Title>General Information About Male Breast Cancer</Title><SummarySection id="_71"><Title>Incidence and Mortality</Title><Para id="_34">Estimated new cases and deaths from breast cancer (men only)  in the United States in 2025:<Reference refidx="1"/></Para><ItemizedList id="_35" Style="bullet"><ListItem>New cases: 2,800.</ListItem><ListItem>Deaths: 510.</ListItem></ItemizedList><Para id="_2">Male breast cancer is rare.<Reference refidx="2"/>  Fewer than 1% of all breast carcinomas occur in
men.<Reference refidx="3"/><Reference refidx="4"/>  The mean age at diagnosis is between 60 and 70 years; however, men of all
ages can be affected by the disease.
</Para></SummarySection><SummarySection id="_223"><Title>Anatomy</Title><Para id="_265"><MediaLink ref="CDR0000694414" type="image/jpeg" alt="Anatomy of the male breast; drawing shows the lymph nodes, nipple, areola, chest wall, ribs, muscle, fatty tissue, and ducts." language="en" placement="image-center-medium" id="_222"><Caption language="en">Anatomy of the male breast. The nipple and areola are shown on the outside of the breast. The lymph nodes, fatty tissue, ducts, and other parts of the inside of the breast are also shown.</Caption></MediaLink></Para></SummarySection><SummarySection id="_74"><Title>Risk Factors</Title><Para id="_3">Predisposing risk factors for male breast cancer appear to include:<Reference refidx="5"/><Reference refidx="6"/>  </Para><ItemizedList id="_224" Style="bullet"><ListItem>Radiation exposure to breast/chest.</ListItem><ListItem>Estrogen
use.</ListItem><ListItem>Diseases associated with hyperestrogenism, such as
cirrhosis or Klinefelter syndrome.</ListItem><ListItem>Family health history: Definite familial
tendencies are evident, with an increased incidence seen in men who have a number of female
relatives with breast cancer.  </ListItem><ListItem>Major inheritance susceptibility: Increased male breast cancer risk has been
reported in families with <GeneName>BRCA</GeneName> pathogenic variants, although risk appears to be higher with inherited <GeneName>BRCA2</GeneName> variants than with <GeneName>BRCA1</GeneName> variants.<Reference refidx="7"/><Reference refidx="8"/>  At age 70 years,  men have an estimated cumulative breast cancer risk of 1.2% if they have  <GeneName>BRCA1</GeneName> pathogenic variants and 6.8% if they have  <GeneName>BRCA2</GeneName> pathogenic variants.<Reference refidx="9"/>  Other genes may be involved in male breast cancer predisposition, including pathogenic variants in the <GeneName>PTEN</GeneName> tumor suppressor gene, <GeneName>TP53</GeneName> (Li-Fraumeni syndrome), <GeneName>PALB2</GeneName>, and in mismatch repair genes associated with Lynch syndrome (also called hereditary nonpolyposis colorectal cancer).<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/> For more information, see the sections on <SummaryRef href="CDR0000062855#_88" url="/types/breast/hp/breast-ovarian-genetics-pdq">High-Penetrance Breast and/or Gynecologic Cancer Susceptibility Genes</SummaryRef> in Genetics of Breast and Gynecologic Cancers, and <SummaryRef href="CDR0000811356#_3496" url="/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq">Male Breast Cancer Screening and Surveillance for <GeneName>BRCA1/2</GeneName> Carriers</SummaryRef> in <GeneName>BRCA1</GeneName> and <GeneName>BRCA2</GeneName>: Cancer Risks and Management.</ListItem></ItemizedList></SummarySection><SummarySection id="_225"><Title>Clinical Features</Title><Para id="_277">Most breast cancers in men present with a retroareolar mass.  Other signs include:  </Para><ItemizedList id="_278" Style="bullet"><ListItem>Nipple retraction. </ListItem><ListItem>Bleeding from the nipple. </ListItem><ListItem>Skin ulceration. </ListItem><ListItem>Peau d’orange. </ListItem><ListItem>Palpable axillary adenopathy. </ListItem></ItemizedList><Para id="_279">Because of delays in diagnosis, breast cancer in men is more likely to present at an advanced stage.<Reference refidx="2"/><Reference refidx="5"/><Reference refidx="13"/></Para></SummarySection><SummarySection id="_228"><Title>Diagnostic Evaluation</Title><Para id="_280">Breast imaging should be performed when  breast cancer is suspected.  The American College of Radiology recommends ultrasonography as the first imaging modality in men younger than 25 years because breast cancer is highly unlikely. Mammography is performed if ultrasonography findings are suspicious.  </Para><Para id="_290">For men aged 25 years or older, or  those who have a highly concerning physical examination, mammography is recommended as the initial test and ultrasonography is useful if mammography is inconclusive or suspicious.<Reference refidx="14"/> Suspicious findings should be confirmed with a core biopsy. If the presence of tumor is confirmed, estrogen receptor, progesterone receptor, and human epidermal growth factor type 2 (HER2) expression/amplification should be evaluated.<Reference refidx="15"/></Para><Para id="_233">For more information, see the <SummaryRef href="CDR0000062787#_6" url="/types/breast/hp/breast-treatment-pdq">Diagnosis</SummaryRef> section in Breast Cancer Treatment.</Para></SummarySection><SummarySection id="_75"><Title>Histopathologic Classification</Title><Para id="_4">Infiltrating
ductal cancer is the most common tumor type of breast cancer in men, while invasive lobular carcinoma is very rare.<Reference refidx="16"/> Breast cancer in men is almost always hormone receptor positive. In a male breast cancer series, 99% of the tumors were estrogen receptor positive, 82% were progesterone receptor positive, 9% were HER2 positive, and 0.3% were triple negative.<Reference refidx="16"/> </Para></SummarySection><SummarySection id="_76"><Title>Prognosis and Predictive Factors</Title><Para id="_281">Tumor size, lymph node involvement, and grade are anatomical prognostic factors, while estrogen receptor, progesterone receptor, and HER2 status are predictive of response to therapy.  </Para><Para id="_282">A more advanced stage at diagnosis confers a worse prognosis for men with breast cancer.<Reference refidx="2"/><Reference refidx="5"/><Reference refidx="13"/> A study found that mortality after breast cancer diagnosis was higher in male patients than in female patients. This disparity appeared to persist after accounting for clinical characteristics, treatment factors, and access to care, suggesting that biological factors and treatment efficacy may play a role.<Reference refidx="17"/>  </Para></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. <ExternalRef xref="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf">Available online</ExternalRef>. Last accessed January 16, 2025.</Citation><Citation idx="2" PMID="15221988">Giordano SH, Cohen DS, Buzdar AU, et al.: Breast carcinoma in men: a population-based study. Cancer 101 (1): 51-7, 2004.</Citation><Citation idx="3" PMID="1319699" MedlineID="92313131">Borgen PI, Wong GY, Vlamis V, et al.: Current management of male breast cancer. A review of 104 cases. Ann Surg 215 (5): 451-7; discussion 457-9, 1992.</Citation><Citation idx="4" PMID="16488803">Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 367 (9510): 595-604, 2006.</Citation><Citation idx="5" PMID="12379069" MedlineID="22266725">Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. Ann Intern Med 137 (8): 678-87, 2002.</Citation><Citation idx="6" PMID="9494523" MedlineID="98155627">Hultborn R, Hanson C, Köpf I, et al.: Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 17 (6D): 4293-7, 1997 Nov-Dec.</Citation><Citation idx="7" PMID="8524414" MedlineID="96112016">Wooster R, Bignell G, Lancaster J, et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (6559): 789-92, 1995 Dec 21-28.</Citation><Citation idx="8" PMID="7658781" MedlineID="95387729">Thorlacius S, Tryggvadottir L, Olafsdottir GH, et al.: Linkage to BRCA2 region in hereditary male breast cancer. Lancet 346 (8974): 544-5, 1995.</Citation><Citation idx="9" PMID="18042939">Tai YC, Domchek S, Parmigiani G, et al.: Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99 (23): 1811-4, 2007.</Citation><Citation idx="10" PMID="20927582">Ding YC, Steele L, Kuan CJ, et al.: Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 126 (3): 771-8, 2011.</Citation><Citation idx="11" PMID="20180015">Silvestri V, Rizzolo P, Zanna I, et al.: PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 122 (1): 299-301, 2010.</Citation><Citation idx="12" PMID="10206076">Boyd J, Rhei E, Federici MG, et al.: Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 53 (1): 87-91, 1999.</Citation><Citation idx="13" PMID="9849414" MedlineID="99066276">Ravandi-Kashani F, Hayes TG: Male breast cancer: a review of the literature. Eur J Cancer 34 (9): 1341-7, 1998.</Citation><Citation idx="14" PMID="26001306">Mainiero MB, Lourenco AP, Barke LD, et al.: ACR Appropriateness Criteria Evaluation of the Symptomatic Male Breast. J Am Coll Radiol 12 (7): 678-82, 2015.</Citation><Citation idx="15" PMID="16079314">Giordano SH: A review of the diagnosis and management of male breast cancer. Oncologist 10 (7): 471-9, 2005.</Citation><Citation idx="16" PMID="32979513">Cardoso F, Paluch-Shimon S, Senkus E, et al.: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31 (12): 1623-1649, 2020.</Citation><Citation idx="17" PMID="31536134">Wang F, Shu X, Meszoely I, et al.: Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncol 5 (11): 1589-1596, 2019.</Citation></ReferenceSection></SummarySection><SummarySection id="_238"><Title>Stage Information for Male Breast Cancer</Title><Para id="_241">Staging for male breast cancer
is identical to staging for female breast cancer.  For more information, see the <SummaryRef href="CDR0000062787#_1994" url="/types/breast/hp/breast-treatment-pdq">TNM Definitions</SummaryRef> section in Breast Cancer Treatment.</Para></SummarySection><SummarySection id="_242"><Title>Treatment Option Overview for Male Breast Cancer</Title><Para id="_243">The approach to the treatment of men with breast cancer is similar to that for women.  Because male breast cancer is rare, there is a lack of randomized data to support specific treatment modalities.  Treatment options for men with breast cancer are described in <SummaryRef href="CDR0000062745#_258" url="/types/breast/hp/male-breast-treatment-pdq">Table 1</SummaryRef>.</Para><Table id="_258"><Title>Table 1.  Treatment Options for Male Breast Cancer</Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry Align="Center">Stage (<SummaryRef href="CDR0000062787#_1994" url="/types/breast/hp/breast-treatment-pdq">TNM Definitions</SummaryRef>)</entry><entry Align="Center">Treatment Options</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; GnRH = gonadotropin-releasing hormone.</entry></Row></TFoot><TBody><Row><entry MoreRows="1">Early/localized/operable male breast cancer</entry><entry><SummaryRef href="CDR0000062745#_298" url="/types/breast/hp/male-breast-treatment-pdq">Surgery with or without radiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062745#_301" url="/types/breast/hp/male-breast-treatment-pdq">Adjuvant therapy</SummaryRef></entry></Row><Row><entry MoreRows="2">Locally advanced male breast cancer</entry><entry><SummaryRef href="CDR0000062745#_311" url="/types/breast/hp/male-breast-treatment-pdq">Neoadjuvant chemotherapy</SummaryRef> </entry></Row><Row><entry><SummaryRef href="CDR0000062745#_311" url="/types/breast/hp/male-breast-treatment-pdq">Surgical excision</SummaryRef></entry></Row><Row><entry> <SummaryRef href="CDR0000062745#_311" url="/types/breast/hp/male-breast-treatment-pdq">Radiation therapy and endocrine therapy</SummaryRef></entry></Row><Row><entry>Metastatic male breast cancer</entry><entry><SummaryRef href="CDR0000062745#_316" url="/types/breast/hp/male-breast-treatment-pdq">Aromatase inhibitor therapy in conjunction with a GnRH agonist</SummaryRef></entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_320"><SectMetaData><SpecificDiagnosis ref="CDR0000041338">male breast cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Early/Localized/Operable Male Breast Cancer</Title><Para id="_295">As in women, treatment options for men with early-stage breast cancer include:</Para><ItemizedList id="_296" Style="bullet">
     <ListItem><SummaryRef href="CDR0000062745#_298" url="/types/breast/hp/male-breast-treatment-pdq">Surgery with or without radiation therapy</SummaryRef> (locoregional therapy).</ListItem><ListItem><SummaryRef href="CDR0000062745#_301" url="/types/breast/hp/male-breast-treatment-pdq">Adjuvant therapy</SummaryRef> (systemic therapy).<ItemizedList id="_297" Style="bullet">
     <ListItem>Chemotherapy.</ListItem><ListItem>Endocrine therapy.</ListItem><ListItem>Human epidermal growth factor receptor 2 (HER2)–directed therapy.</ListItem></ItemizedList></ListItem></ItemizedList><SummarySection id="_298"><Title>Surgery With or Without Radiation Therapy</Title><Para id="_299">Primary treatment is a mastectomy with axillary
lymph node dissection.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/> Responses in men are generally similar to those seen in women with breast cancer.<Reference refidx="2"/> Breast conservation surgery with lumpectomy and radiation therapy has also been used and can be offered if standard criteria for breast conservation therapy are met. Results in men have been similar to those seen in women with breast cancer.<Reference refidx="4"/></Para><Para id="_300">For more information, see the <SummaryRef href="CDR0000062787#_2573" url="/types/breast/hp/breast-treatment-pdq">Surgical Treatment for Breast Cancer</SummaryRef> section in Breast Cancer Treatment.</Para></SummarySection><SummarySection id="_301"><Title>Adjuvant Therapy</Title><Para id="_302">The optimal systemic treatment in men with breast cancer has not been studied in randomized clinical trials. Adjuvant therapy should be administered according to the same criteria used for women. Adjuvant therapies used to treat early/localized/operable male breast cancer are outlined in <SummaryRef href="CDR0000062745#_308" url="/types/breast/hp/male-breast-treatment-pdq">Table 2</SummaryRef>. For more information, see the <SummaryRef href="CDR0000062787#_2687" url="/types/breast/hp/breast-treatment-pdq">Systemic Therapy for Stages I, II, and III Breast Cancer</SummaryRef> section in Breast Cancer Treatment.</Para><Table id="_308">
     <Title>Table 2.  Adjuvant Therapy Used to Treat Early/Localized/Operable Male Breast Cancer</Title>
      <TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry Align="Center">Type of Adjuvant Therapy</entry><entry Align="Center">Agents Used</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">HER2 = human epidermal growth factor receptor 2; LHRH = luteinizing hormone-releasing hormone.</entry></Row></TFoot><TBody><Row><entry MoreRows="1">Chemotherapy</entry><entry>Docetaxel and cyclophosphamide</entry></Row><Row><entry>Doxorubicin plus cyclophosphamide with or without paclitaxel</entry></Row><Row><entry MoreRows="1">Endocrine therapy</entry><entry>Tamoxifen <Reference refidx="5"/></entry></Row><Row><entry>Aromatase inhibitors with LHRH agonist <Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/></entry></Row><Row><entry MoreRows="1">  HER2-directed therapy</entry><entry>Trastuzumab <Reference refidx="1"/><Reference refidx="5"/></entry></Row><Row><entry>Pertuzumab</entry></Row></TBody></TGroup>
     </Table><Para id="_323"><Strong>Tamoxifen</Strong></Para><Para id="_322">Evidence (tamoxifen):</Para><OrderedList id="_292" Style="Arabic"><ListItem>A retrospective analysis of 257 men with stage I to stage III breast cancer included 50 men who were treated with an aromatase inhibitor (AI) and 207 men who were treated with tamoxifen.<Reference refidx="10"/><ItemizedList id="_293" Style="bullet"><ListItem>With a median follow-up of 42 months, treatment with an AI was associated with a higher risk of death compared with tamoxifen (32% with AI vs. 18% with tamoxifen; hazard ratio, 1.55; 95% confidence interval, 1.13–2.13).</ListItem></ItemizedList></ListItem></OrderedList><Para id="_284">In men with contraindications for tamoxifen, single-agent AI therapy is not recommended.  AIs should be combined with gonadotropin-releasing hormone (GnRH) analogues.<Reference refidx="6"/> </Para><Para id="_285">In male breast cancer patients, tamoxifen
use is associated with a high rate of treatment-limiting symptoms such as hot
flashes and impotence.<Reference refidx="11"/></Para><Para id="_307">The German Breast Group conducted a randomized phase II clinical trial (<ProtocolRef nct_id="NCT01638247">NCT01638247</ProtocolRef>) of tamoxifen 
with or without a GnRH analogue versus AI plus a GnRH 
analogue in men with early-stage, hormone receptor–positive breast cancer. Results of this trial are 
pending.  </Para></SummarySection><SummarySection id="_TrialSearch_320_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_320_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1319699" MedlineID="92313131">Borgen PI, Wong GY, Vlamis V, et al.: Current management of male breast cancer. A review of 104 cases. Ann Surg 215 (5): 451-7; discussion 457-9, 1992.</Citation><Citation idx="2" PMID="12379069" MedlineID="22266725">Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. Ann Intern Med 137 (8): 678-87, 2002.</Citation><Citation idx="3" PMID="1829945" MedlineID="91299456">Kinne DW: Management of male breast cancer. Oncology (Huntingt) 5 (3): 45-7; discussion 47-8, 1991.</Citation><Citation idx="4" PMID="17606375">Golshan M, Rusby J, Dominguez F, et al.: Breast conservation for male breast carcinoma. Breast 16 (6): 653-6, 2007.</Citation><Citation idx="5" PMID="16079314">Giordano SH: A review of the diagnosis and management of male breast cancer. Oncologist 10 (7): 471-9, 2005.</Citation><Citation idx="6" PMID="16849742">Giordano SH, Hortobagyi GN: Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24 (21): e42-3, 2006.</Citation><Citation idx="7" PMID="1588379" MedlineID="92268955">Cocconi G, Bisagni G, Ceci G, et al.: Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 10 (6): 984-9, 1992.</Citation><Citation idx="8" PMID="8293400" MedlineID="94123236">Gale KE, Andersen JW, Tormey DC, et al.: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 73 (2): 354-61, 1994.</Citation><Citation idx="9" PMID="23722469">Zagouri F, Sergentanis TN, Koutoulidis V, et al.: Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108 (11): 2259-63, 2013.</Citation><Citation idx="10" PMID="23224235">Eggemann H, Ignatov A, Smith BJ, et al.: Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137 (2): 465-70, 2013.</Citation><Citation idx="11" PMID="8004585" MedlineID="94273098">Anelli TF, Anelli A, Tran KN, et al.: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74 (1): 74-7, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_310"><SectMetaData><SpecificDiagnosis ref="CDR0000041338">male breast cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Locally Advanced Male Breast Cancer</Title><Para id="_311">Treatment options for men with locally advanced breast cancer include:<Reference refidx="1"/></Para><ItemizedList id="_312" Style="bullet">
     <ListItem>Neoadjuvant chemotherapy. </ListItem><ListItem>Surgical excision.</ListItem><ListItem>Radiation therapy and endocrine therapy.</ListItem></ItemizedList><Para id="_286">The decisions regarding the order and choice of treatments in men are guided by the same principles used for the treatment of breast cancer in women (in particular, evaluation of pathological response).<Reference refidx="1"/><Reference refidx="2"/> </Para><Para id="_314">For more information, see the <SummaryRef href="CDR0000062787#_1440" url="/types/breast/hp/breast-treatment-pdq">Treatment of Locoregional Recurrent Breast Cancer</SummaryRef> section in Breast Cancer Treatment.</Para><SummarySection id="_TrialSearch_310_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_310_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="12379069" MedlineID="22266725">Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. Ann Intern Med 137 (8): 678-87, 2002.</Citation><Citation idx="2" PMID="18210656">Kamila C, Jenny B, Per H, et al.: How to treat male breast cancer. Breast 16 (Suppl 2): S147-54, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_315"><SectMetaData><SpecificDiagnosis ref="CDR0000041338">male breast cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Metastatic Male Breast Cancer</Title><Para id="_316">Treatment options for men with metastatic breast cancer include:</Para><ItemizedList id="_317" Style="bullet">
     <ListItem>Aromatase inhibitor (AI) therapy in conjunction with a gonadotropin-releasing hormone (GnRH) agonist. </ListItem></ItemizedList><Para id="_287">The management of metastatic hormone receptor–positive male breast cancer relies on the same treatment options used in women. However, data regarding the activity of AIs with GnRH agonists and fulvestrant in men are limited to case series.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> The administration of an AI in conjunction with a GnRH agonist is recommended on the basis of the adjuvant data. There are no data comparing the activity of fulvestrant alone with fulvestrant in combination with a GnRH agonist. </Para><Para id="_288">Based on real world data and limited studies, it is reasonable to extrapolate the use of additional treatment options for men. These treatment options include cyclin-dependent kinase (CDK) 4/6 inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and phosphatidylinositol-3 kinase (PI3K) inhibitors, used in combination with endocrine therapy. </Para><Para id="_289">The use of chemotherapy, human epidermal growth factor receptor 2 (HER2)-targeted therapy, immunotherapy, and poly (ADP-ribose) polymerase (PARP) inhibitors in men with metastatic breast cancer is guided by similar treatment principles as in women.<Reference refidx="5"/><Reference refidx="6"/></Para><Para id="_319">For more information, see the <SummaryRef href="CDR0000062787#_1452" url="/types/breast/hp/breast-treatment-pdq">Treatment of Metastatic Breast Cancer</SummaryRef> section in Breast Cancer Treatment.</Para><SummarySection id="_TrialSearch_315_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_315_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="25238881">Di Lauro L, Vici P, Barba M, et al.: Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Res Treat 148 (1): 73-80, 2014.</Citation><Citation idx="2" PMID="25519043">Zagouri F, Sergentanis TN, Chrysikos D, et al.: Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat 149 (1): 269-75, 2015.</Citation><Citation idx="3" PMID="23722469">Zagouri F, Sergentanis TN, Koutoulidis V, et al.: Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108 (11): 2259-63, 2013.</Citation><Citation idx="4" PMID="23982884">Di Lauro L, Vici P, Del Medico P, et al.: Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat 141 (1): 119-23, 2013.</Citation><Citation idx="5" PMID="12379069" MedlineID="22266725">Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. Ann Intern Med 137 (8): 678-87, 2002.</Citation><Citation idx="6" PMID="18210656">Kamila C, Jenny B, Per H, et al.: How to treat male breast cancer. Breast 16 (Suppl 2): S147-54, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_27"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (02/28/2025)</Title><Para id="_28">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_330"><Strong><SummaryRef href="CDR0000062745#_1" url="/types/breast/hp/male-breast-treatment-pdq">General Information About Male Breast Cancer</SummaryRef></Strong></Para><Para id="_331">Updated <SummaryRef href="CDR0000062745#_34" url="/types/breast/hp/male-breast-treatment-pdq">statistics</SummaryRef> with estimated new cases and deaths for 2025 (cited American Cancer Society as reference 1).  </Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062745#_AboutThis_1" url="/types/breast/hp/male-breast-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of male breast cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Male Breast Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Fumiko Chino, MD (MD Anderson Cancer Center)</ListItem><ListItem>Tarek Hijal, MD (McGill University Health Centre)</ListItem><ListItem>Joseph L. Pater, MD (NCIC-Clinical Trials Group)</ListItem><ListItem>Carol Tweed, MD (Maryland Oncology Hematology)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Male Breast Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq">https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389234]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2025-02-28</DateLastModified></Summary>
